In partnership with
Exploring AI Voice With SuperBloom
Scaling a campaign globally means finding a voice that resonates everywhere, without losing the overall message. For Deel's "Feeling of Deeling" campaign, agency SuperBloom needed exactly that: a consistent brand voice across markets, deployed fast, without sacrificing quality or consent. They built it with Branded AI Voice, powered by real, professional talent.
SuperBloom and Voices break down how the campaign came to life in this on-demand video session, from strategic talent selection through seamless production workflows and global scale, to the governance that future-proofs an audio strategy built to last. You'll hear directly from the team on how they made this happen, plus their advice if you're looking to explore AI voice for your brand.
If you're a marketing executive, agency creative, or brand leader mapping campaigns in international markets, watch this on-demand session to get a real playbook, not a hypothetical, lessons any creative team can apply to their own global rollout.
In today's Signal:
UK MHRA commission proposes 44 recommendations for NHS AI, introducing staged "L-plate" authorisations and mandatory post-deployment monitoring.
ARPA-H commits 2.7M through ADVOCATE to develop autonomous 24/7 cardiac AI agents with UpDoc, Atman Health, and Tempus AI.
Implicity secures 0M growth equity from IRIS and Five Arrows to scale AI-driven cardiac monitoring across 120,000+ patients daily.
Follow the money: .1B for Frazier Life Sciences Public Fund and 2.5M for TwoStep Therapeutics as capital rotates toward clinical de-risking
Quick Hits: Bayer wins first-line FDA nod for sevabertinib, Telix awaits Pixclara brain cancer imaging verdict, and Doximity/Hims report AI operating margins
REGULATION
1. The UK proposes "L-plate" approvals and continuous audits for healthcare AI.
Source: UK Government / Medicines and Healthcare products Regulatory Agency (MHRA), September 10, 2026.
The signal: The National Commission into the Regulation of AI in Healthcare, hosted by the MHRA, delivered 44 recommendations proposing provisional staged authorisations and mandatory post-deployment monitoring for medical AI.
The details:
Chaired by practicing NHS clinicians Professor Alastair Denniston and Professor Henrietta Hughes, the report synthesized input from over 12,000 clinicians, patients, and industry leaders across a 12-month inquiry.
The staged authorisation model introduces provisional "L-plate" licenses, allowing AI models to deploy in real NHS clinics under tight supervision before receiving full marketing clearance.
MHRA Chief Executive Lawrence Tallon warned that legacy device frameworks designed for static hardware fail to capture adaptive models that learn and drift over time, necessitating continuous lifecycle surveillance and explicit patient consent.
Why it matters: Static, point-in-time regulatory clearances cannot govern software that drifts as clinical data evolves. The UK is establishing the first practical playbook for perpetual post-market AI oversight. For HealthTech developers, compliance is no longer a one-time premarket milestone but a permanent line item in operating expenditure.
AGENTIC AI
2. ARPA-H commits 2.7M to build autonomous 24/7 cardiac AI agents.
Source: Advanced Research Projects Agency for Health (ARPA-H), Program ADVOCATE, September 2026.
The signal: ARPA-H selected UpDoc, Atman Health, and Tempus AI under its ADVOCATE program to develop patient-facing AI agents that autonomously manage heart failure medications, lab orders, and specialist triage.
The details:
Program manager Dr. Haider Warraich, a practicing cardiologist, framed ADVOCATE as a direct response to specialist access deserts, noting that nearly 46% of U.S. counties lack a single practicing cardiologist while heart failure drives over 200,000 preventable deaths annually.
UpDoc was awarded up to .2M with support from Microsoft, OpenAI, and NVIDIA; Atman Health received up to .7M for voice-first care; and Tempus AI was selected to expand its clinical intelligence platform.
The 39-month initiative requires performers to submit an FDA authorization package within 24 months, with Stanford University building a dedicated supervisory oversight AI and Duke Health and Kaiser Permanente validating real-world EHR deployment across 21 medical centers.
Why it matters: This is the federal government explicitly funding the transition from passive AI scribes to autonomous prescribing agents. By pairing direct-care agents with an independent supervisory overseer, ARPA-H is laying down the safety architecture the FDA needs to clear high-risk autonomous medicine.
CLINICAL AI
3. Implicity lands 0M to scale AI remote monitoring that cuts cardiac deaths by 26%.
Source: Implicity / IRIS / Five Arrows (Rothschild & Co) / Heart Rhythm study, September 2026.
The signal: French digital health leader Implicity secured a 0 million growth equity round led by IRIS and Rothschild & Co's Five Arrows to expand its universal cardiac remote monitoring platform across U.S. health systems.
The details:
Founded by electrophysiologist Dr. Arnaud Rosier, Implicity's platform normalizes transmissions across implantable pacemakers and defibrillators from Medtronic, Boston Scientific, Abbott, and Biotronik into a unified EHR workflow for over 250 medical centers and 120,000+ patients daily.
Peer-reviewed clinical validation in Heart Rhythm demonstrated a 26% reduction in patient mortality and a 4% decrease in hospitalizations compared to conventional remote monitoring.
The platform's FDA-cleared ECG Analyzer eliminates up to 76% of false-positive arrhythmia alarms, allowing cardiology teams to scale patient panels from 250 to 5,000 without adding administrative headcount.
Why it matters: Remote monitoring failed historically because device data flooded hospital clinics with unmanageable alert noise. Implicity proves that combining universal device interoperability with predictive alert-filtering unlocks massive clinical leverage. Hospital CFOs and cardiology chairs buy noise reduction, not more raw dashboards.